Somatic vs Germline Mutations: The Difference That Changes Everything

One of the most important distinctions in modern medicine is one most patients have never heard of. Whether a mutation is somatic or germline determines what test you should get, what the result actually means, and what you can pass to your children. Here is the difference, why it matters, and where the line between the two is blurring.

Presented By Our Partners

A woman in her early forties walks into her oncologist’s office and learns that her newly diagnosed breast tumor carries a mutation in BRCA1, one of the most famous genes in cancer medicine. The news arrives with two very different futures attached to it.

If the mutation is what doctors call germline, she has carried it since the moment she was conceived. It is in every cell of her body. She inherited it from one of her parents, and there is a fifty percent chance she has passed it to each of her own children. Her sister, her brother, her cousins on the affected side of the family all have a one-in-two chance of carrying it themselves. The conversation in the room shifts from her tumor to her family.

If the mutation is somatic, it arose inside the tissue that became the tumor. It is not in her healthy cells. She did not inherit it. She cannot pass it on. The conversation stays in the room.

The mutation in her tumor looks identical under a sequencer either way. The clinical implications could not be more different. The distinction between somatic and germline is the single most consequential boundary line in the genetics of disease, and it is one that almost no patient is taught to think about until they are sitting across from a doctor receiving news they did not expect.

Two ways a mutation can enter your story

Every cell in your body contains a copy of your genome. The question of whether a particular mutation is somatic or germline comes down, in essence, to a simple matter of timing.

A germline mutation was already there when you were one cell. It existed in the egg or the sperm cell that combined to make you, which means it was copied into the first cell of your existence and then, faithfully, into every cell that descended from that one. By the time you were born, every cell in your body carried it. By the time you have children, the mutation will be present in your eggs or sperm, and your children have a fifty percent chance of inheriting it. This is what makes germline mutations hereditary. They travel through families because they live in the cells that build the next generation.

A somatic mutation appeared sometime after that first cell. It might have happened when you were an embryo and only a few hundred cells old. It might have happened in a stem cell in your bone marrow when you were forty. It might have happened in a sun-exposed skin cell last summer. Whenever it occurred, the mutation lives only in the cell where it appeared and in that cell’s descendants. It does not exist in your egg or sperm cells. It cannot be passed to your children. We have written a foundational explainer on what somatic mutations are and how they arise; this piece focuses specifically on how they differ from inherited mutations and why the difference matters.

Two ways the same letter change in the same gene can end up in the same tissue, with completely different consequences for the person carrying it and for everyone in their family.

What the distinction actually predicts

The somatic-versus-germline distinction is not academic. It determines, in concrete clinical terms, several things at once.

Whether your relatives are at risk. A germline mutation in a cancer-risk gene like BRCA1, BRCA2, MLH1, MSH2, APC, or TP53 means that your siblings, parents, and children may be carrying the same mutation. They can choose to undergo genetic testing, increased screening, or in some cases preventive surgery. A somatic mutation in the same gene means none of this. Your family is at no elevated risk from your tumor. The mutation arose only in the cells that became cancer.

Whether you are at elevated risk for additional cancers. Germline carriers of a mutation in a tumor suppressor gene are at elevated risk for cancers in other tissues for the rest of their lives, because the same broken gene is sitting in every cell. Women with a germline BRCA1 mutation have a roughly forty to fifty percent lifetime risk of developing breast cancer, sometimes higher, plus a substantial elevated risk of ovarian, pancreatic, and other cancers. Men with germline BRCA mutations are at increased risk for prostate, breast, and pancreatic cancer. A somatic mutation in BRCA1, found only in a single tumor, does not carry these implications. Once that tumor is treated, the rest of the body’s cells are no different from anyone else’s.

What kind of testing makes sense. Germline genetic testing is performed on a sample of your healthy cells, typically blood or saliva. The mutation, if present, will be in every cell of those samples, and the lab can detect it cleanly. Somatic testing, also called tumor sequencing, is performed on a sample of the tumor itself, because that is the only place the mutation lives. The two tests answer different questions and are sometimes both ordered for the same patient. Confusing them is one of the most common sources of misunderstanding in cancer genetics.

What treatments may work. Several modern targeted cancer therapies, particularly the PARP inhibitors used in BRCA-related ovarian and breast cancer, are effective whether the BRCA mutation in the tumor is germline or somatic. The drug works on the broken gene, not on the patient’s family history. This is why guidelines now often recommend tumor sequencing for ovarian cancer regardless of germline status: it can reveal somatic mutations that open new treatment options even when no inherited mutation is found.

The two-hit model and why it matters here

The cleanest way to see how somatic and germline mutations interact in real disease is through what cancer geneticists call the two-hit model, first proposed by Alfred Knudson in 1971.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

The model is simple to state. Most genes that prevent cancer come in two copies, one from each parent. To lose the protective function of the gene, a cell needs to break both copies. In someone without an inherited mutation, both copies start out intact. For a cell to lose protection, it has to acquire two independent somatic mutations, each disabling one copy of the gene. The probability of this happening in any given cell is small. Cancer arises only after years or decades, when the dice happen to land badly in some unlucky cell.

In someone who inherits a germline mutation, the math changes dramatically. Every cell in the body already starts with one copy of the gene broken from birth. To lose protection, the cell needs only one additional somatic hit, not two. The probability of cancer is no longer the square of the small per-cell mutation rate. It is approximately the per-cell mutation rate itself. The result is that hereditary cancer syndromes are characterized by earlier onset, multiple primary tumors, and high lifetime risk, because the somatic dice only have to roll once in any of trillions of cells, instead of twice.

This is why a forty-year-old woman with a germline BRCA1 mutation faces a profoundly elevated breast cancer risk while her unaffected sister, without the inherited mutation, has roughly the average risk of any woman her age. Same gene, same possible somatic event, but a fundamentally different starting position.

The two-hit model also explains why most cancers, even in people without any inherited mutation, are still ultimately driven by mutations in the same set of cancer genes. The pathway to disease is the same. The difference is only how many of the steps you started with already taken.

The numbers, in rough proportions

For cancer specifically, where the somatic-versus-germline distinction has been studied longest and most carefully, the broad statistics are worth knowing.

Roughly five to ten percent of all cancers are caused primarily by inherited germline mutations. These are the cancers that cluster in families, often appear at unusually young ages, and follow recognizable hereditary patterns. More than three hundred distinct hereditary cancer syndromes have been described.

The remaining ninety to ninety-five percent of cancers are what doctors call sporadic, meaning they arise from somatic mutations accumulated during the patient’s lifetime, often without any obvious family pattern. Sporadic cancer is not random in any deep sense; it is shaped by environmental exposures, lifestyle, infection history, and the slow accumulation of replication errors over decades. But it is not inherited.

An additional ten to fifteen percent of cancers are sometimes called familial, meaning they cluster in families more than chance would predict but cannot be tied cleanly to a single inherited mutation. These probably reflect a combination of multiple low-impact inherited variants, shared environmental exposures, and accumulated somatic mutations.

The implication is that for any given patient with cancer, the most likely source of the mutation driving the disease is somatic. Hereditary cancer is real and important and worth identifying when it is present. It is not, however, the typical case.

Where the line is blurring

The clean two-category distinction has worked well for most of the history of cancer genetics, but the new science of somatic mosaicism is beginning to complicate it in interesting ways.

The complication is what happens when a “somatic” mutation occurs very early in development.

If a mutation arises in the first cell after fertilization, it ends up in every cell of the resulting body, indistinguishable from a germline mutation in clinical terms even though it was technically acquired rather than inherited. If a mutation arises a little later, in one of the first few embryonic cells, it ends up in a substantial fraction of the body’s tissues, a condition called mosaicism. If it arises later still, it might be confined to a single organ system, or to a few patches of skin. The boundary between germline and somatic, in other words, is more of a gradient than a wall.

This matters clinically in several settings. A patient may carry an apparent de novo germline mutation, meaning a mutation present in the patient but not detectable in either parent. Some of these patients are true germline carriers; in others, one parent has the mutation as a somatic mosaic, present in some of their cells (sometimes including their egg or sperm cells) but missed by standard germline testing. Up to five percent of seemingly de novo cases may turn out, on careful analysis, to involve parental mosaicism. The implication for genetic counseling is real: a parent who tests negative on a blood-based germline test could still pass the mutation to additional children if they carry mosaicism in their reproductive cells.

The other place the line blurs is in clonal hematopoiesis (CHIP) and similar conditions, where somatic mutations in blood-forming stem cells expand into populations large enough that they appear, on standard testing, as if they might be germline. We have written separately about CHIP and its cardiovascular implications; for present purposes, the relevant point is that the variant allele frequency on a sequencing report (the proportion of DNA reads carrying the mutation) is now a routine clue to whether a finding is likely germline (around fifty percent) or somatic (typically much lower). Modern molecular pathology often uses tumor-normal sequencing, comparing tumor DNA to a sample of healthy tissue from the same patient, to settle the question definitively.

What this means for your health

For the average reader without a strong family history of cancer, the practical implications of the somatic-versus-germline distinction are limited but worth knowing.

First, when you hear the phrase “genetic testing,” it almost always refers to germline testing for inherited mutations. This is the test that informs your family’s risk and your own lifetime risk for additional cancers. It is appropriate when you have a family history that includes early-onset cancer, multiple primary cancers in one person, particular rare cancer types, or known hereditary cancer syndromes in your relatives. Genetic counselors are the right professionals to discuss whether testing makes sense for you.

Second, if you or someone in your family is diagnosed with cancer, the tumor itself may be sequenced. This is somatic testing, and its purpose is to guide treatment. Increasingly, when a tumor sequencing report identifies a mutation in a gene like BRCA1/2, TP53, MLH1/MSH2/MSH6, or other cancer-susceptibility genes, the patient should also undergo germline testing to determine whether the mutation in the tumor was inherited. The findings can substantially change family screening recommendations.

Third, the broad picture is that most cancer in most people is driven by somatic mutations accumulated over decades, shaped by exposures and choices and luck. The same is true for the growing list of non-cancer conditions, including somatic mutations in autoimmune disease and CHIP-related cardiovascular risk, in which somatic mutations in non-cancer tissues appear to drive disease through mechanisms separate from inheritance. We are entering an era in which both kinds of mutation matter, and the right test depends on the right question.

The single most useful frame for a non-specialist is this. Germline mutations are about your family. Somatic mutations are about your tissues. Germline tests answer questions about who else might be at risk and what cancers you yourself should watch for. Somatic tests answer questions about how to treat a specific tumor or measure the cellular evolution happening inside a specific organ. Both are useful. They are not interchangeable. And the next decade of medicine will increasingly involve ordering both, and reading the answers in concert.

Frequently asked questions

What is the main difference between somatic and germline mutations?

Germline mutations are inherited from a parent and present in every cell of the body, including the egg or sperm cells, which means they can be passed to children. Somatic mutations arise during a person’s lifetime in body cells, are present only in the cell where they occurred and its descendants, and cannot be inherited or passed on.

How do I know whether my mutation is somatic or germline?

The simplest indicator is the type of test. Germline testing is performed on healthy tissue, typically blood or saliva, and finds inherited mutations present in every cell. Somatic testing is performed on diseased tissue, typically a tumor biopsy, and finds mutations present only in those cells. When ambiguity arises, paired tumor-normal sequencing or analysis of variant allele frequency can usually settle the question.

If my tumor has a BRCA mutation, do my relatives need to be tested?

Possibly, yes. A BRCA mutation found in a tumor may have been inherited (germline) or may have arisen during the cancer’s development (somatic). If germline testing on healthy tissue confirms the mutation is inherited, first-degree relatives have a fifty percent chance of carrying it and may benefit from genetic counseling and testing. If germline testing is negative, the mutation is somatic and your relatives are not at elevated risk from your tumor.

Can somatic mutations be inherited by my children?

No. Somatic mutations occur in body cells (somatic cells), not in the egg or sperm cells (germ cells) that combine to make a child. Only mutations present in the germ cells can be passed on. Rare exceptions exist when a parent has somatic mosaicism that includes their reproductive cells, but in standard cases, somatic mutations stay with the individual who acquired them.

What proportion of cancers are hereditary?

Roughly five to ten percent of all cancers are primarily caused by inherited germline mutations in cancer-susceptibility genes. The remaining ninety to ninety-five percent are sporadic, driven by somatic mutations accumulated over a lifetime. An additional ten to fifteen percent of cancers cluster in families more than chance would predict but cannot be tied to a single inherited mutation; these are often called familial.

Can the same gene be mutated either somatically or in the germline?

Yes. The classical examples are tumor suppressor genes like BRCA1, BRCA2, TP53, and the mismatch repair genes (MLH1, MSH2, MSH6, PMS2). The same DNA sequence change can arise as an inherited germline mutation, present from birth, or as a somatic mutation acquired during a lifetime in a single tissue. The mutation looks identical at the molecular level. The clinical and family implications are very different.

If I am healthy, should I get germline genetic testing?

For most healthy adults without strong family history of cancer, routine germline cancer testing is not recommended. Testing is most useful when you have a family or personal history that suggests possible hereditary cancer risk, including early-onset cancer, multiple primary cancers, certain rare cancer types, or known hereditary syndromes in close relatives. A genetic counselor is the right professional to discuss whether testing is appropriate for your specific situation.

This piece is part of an ongoing series on the Mosaic Body, the emerging view of human biology in which acquired DNA changes shape health, disease, and aging. See also our pillar essay on why your cells are quietly mutating, and why it’s rewriting medicine, our foundational explainer on what somatic mutations are, our coverage of clonal hematopoiesis and cardiovascular risk, our piece on somatic mutations and autoimmune disease, the framework of mosaic aging, and our review of Beyond Inheritance by Roxanne Khamsi.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.